Clinical Research Site & Patient Recruitment Service
Daxia means "Big Hero"
We love what heroes look like.
Diverse Human Biologicals with Clinical Data You Can Rely On
About Daxia
Biosample Collections
Daxia partners with clinicians across South Florida to provide specialty human biologics and patient remnant samples for custom IRB approved protocols, as well as Phase II and Phase III drug studies. We are FDA regulated, IATA, CLIA, GCP, GMP and ISO certified. We largely serve the in vitro diagnostics and early stage therapeutic industries with preclinical, raw materials, and controls for validation. We are a non-SMO multi-investigator, multi-TA research site across multiple locations focused in areas of neurology, oncology, autoimmune, rare disease, gastroenterology, infectious, and cardiology.
Patient Engagement Services
Daxia Health is a patient engagement service provider offering clinical trial outreach solutions for engaging underrepresented communities. We engage, recruit, and train minority physicians and their staff so that they are research-ready within our network and we directly recruit patients in the community through grass roots marketing and patient advocacy partnerships.
Daxia is Derived From the Chinese Word “ Da Xia” Meaning “Big Hero”
​
We strive to serve the biggest heroes — our patient and physician communities who are fighting disease every day. Pharma can be a big hero too by bringing new treatments and even cures to all types of people, making sure that your trials and therapeutic products reach culturally diverse individuals. Do something real to make a difference.
Case Studies
132 patients 24 Month Enrollment NSCLC Stage III Diagnostics Study Demographic breakdown Race: 66% African American 19% White 4% Asian 2% Native American Ethnicity: 41% Hispanic or Latino
54 patients 18 Month Enrollment Alzheimer's Disease Phase 2b IV study Demographic breakdown Race: 64% African American 18% White 11% Asian 4% Native American Ethnicity: 31% Hispanic or Latino
143 patients 4 Month Enrollment MS with active COVID Diagnostic Study Demographic breakdown Race: 67% African American 11% White 6% Asian 1% Native American 1% Native Hawaiian Ethnicity: 27% Hispanic or Latino
118 patients 2 months SLE patients with severe nephritis in a medical diagnostic device trial Diverse enrollment: 62% African American 31% Hispanic 3% Native American
Enrolled 137 patients across two sister studies for Crohn's and UC, Phase III investigational drug studies Enrollment period 20 months Demographics: 59% African American 27% Hispanic 8% Asian 2% Asian Pacific Islander 2% Native American
58 enrolled patients 6 month enrollment Phase III drug study 64% African American 41% Hispanic of which 11% identified as Black Hispanic 3% Asian 2% Native American
11 Daxia sites (or sister company sites) 5221 Patients Enrolled 6 month enrollment RF antibody biosample study 48% African American 31% Hispanic of which, 6% identified as Black Hispanic 2% Native American 2% Asian 1% Alaskan Native
14 Daxia Sites (or sister company sites) 8477 Patients Enrolled A1C biosample study 6 month enrollment 55% African American 28% Hispanic of which, 8% identified as Black Hispanic 4% Native American 2% Asian 1% Alaskan Native
12 Daxia sites (or sister company sites) 1751 patients enrolled Diagnostic sample study 3 month enrollment 46% African American 30% Hispanic of which, 11% identify as Black Hispanic 8% Native American 4% Native Hawaiian 2% Asian
8 Daxia Sites (or sister company sites) 4419 PCR+ patients Diagnostic device study 3 month enrollment Demographics: 54% African American 32% Hispanic of which, 9% identified as Black Hispanic 5% Native American 3% Asian
Empowering Health Equity
Pioneering Unique Research Solutions
Daxia is a Native American owned and founded company working to revolutionize specialty biologicals and trial recruitment across the healthcare industry. With a deep-rooted passion for equitably advancing human health, we are dedicated to creating inclusive and impactful solutions that drive positive change in the medical research community. Our work touches every aspect of the R&D cycle from preclinical biospecimens and raw materials, to diagnostic validation and point-of-care devices, to therapeutic development. As a result, our mission is to empower all patients from all backgrounds to be represented in clinical data -- which not only broadens the characterization and richness of our product & service offerings, but ultimately leads to more meaningful and effective outcomes across all of medicine.
​​
​
